NASDAQ:IMMU
Delisted
Immunomedics Stock News
$87.86
+0 (+0%)
At Close: May 27, 2022
Immunomedics' Shares Surge YTD on Cancer Drug Approval
02:36pm, Monday, 06'th Jul 2020
Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The.
Immunomedics' Shares March Higher, Can It Continue?
10:49am, Monday, 06'th Jul 2020
As of late, it has definitely been a great time to be an investor in Immunomedics.
Immunomedics, Inc. (NASDAQ:IMMU) Shares Purchased by Invesco Ltd.
05:08am, Monday, 06'th Jul 2020
Invesco Ltd. raised its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 5.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 544,965 shares of the
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
HighTower Advisors LLC Sells 522 Shares of Immunomedics, Inc. (NASDAQ:IMMU)
08:18am, Sunday, 05'th Jul 2020
HighTower Advisors LLC trimmed its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 1.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The f
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
08:05pm, Thursday, 02'nd Jul 2020
The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the
Top U.S. stock picks from BofA and Wells Fargo
11:17am, Thursday, 02'nd Jul 2020
Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
12:00am, Wednesday, 01'st Jul 2020
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer.
Shareholder Alert: Robbins LLP Announces It Is Investigating Immunomedics, Inc. (IMMU) for Misleading Shareholders
08:25pm, Monday, 29'th Jun 2020
Shareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. (NASDAQ: IMMU) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's off
Shareholder Alert: Robbins LLP Reminds Investors Shareholder Class Action Against Immunomedics, Inc. (IMMU) Survives Motion to Dismiss
10:01pm, Wednesday, 24'th Jun 2020
Shareholder rights law firm Robbins LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQ: IMMU) filed a class action complaint against the company for alleged violations of the Securiti
Mercury : Leading the Way With Edge Processing | MarketScreener
05:00pm, Wednesday, 24'th Jun 2020Shareholder Alert: Robbins LLP Reminds Investors Shareholder Class Action Against Immunomedics, Inc. (IMMU) Survives Motion to Dismiss
12:00am, Wednesday, 24'th Jun 2020
Shareholder rights law firm Robbins LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQ: IMMU) filed a class action complaint against
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
12:00am, Tuesday, 23'rd Jun 2020
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
Immunomedics, Inc. (NASDAQ:IMMU) Stock Holdings Lifted by M&T Bank Corp
06:46am, Sunday, 21'st Jun 2020
M&T Bank Corp lifted its holdings in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 4.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commissi
